Bonjour,
Je souhaitais simplement partager cet article : https://www.medscape.com/viewarticle/936578
(créer un compte est gratuit, vous aurez ensuite accès à la totalité de l'article).
Il semble que les patients atteints de cancers du sang soient un terrain favorable pour les formes sévères provoquées par la COVID 19.
Soyez prudents !
Estelle
Je vous mets la copie de l'article ici :
Hematologic Cancers Tied to More Severe COVID-19 Illness
Roxanne Nelson, RN, BSN
August 31, 2020
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.
Patients with cancer are purported to have poor outcomes from COVID-19 infection, but the type of cancer makes a difference in the severity of illness, according to new findings from the UK.
Patients with hematologic cancers (leukemia, lymphoma, and myeloma) had a more severe COVID-19 trajectory compared to patients with solid organ tumors in the UK Coronavirus Cancer Monitoring Project (UKCCMP) cohort, report Lennerd Lee, BMBCh, PhD, of the Institute of Cancer and Genomic Sciences, University of Birmingham, UK, and colleagues.
For example, patients with hematologic cancers were more likely to require treatment in an intensive care unit.
Furthermore, patients with leukemia had a more than twofold risk of COVID-19–related death compared with the rest of the cohort.
Similar to results seen in the general population, increasing age and sex were predominant risk factors for COVID-19 infection and disease severity for most patients with cancer, the study authors also report.
The study was published online August 24 in The Lancet Oncology.
The new data add to the literature on COVID-19 and cancer. Previous studies have reported that patients with COVID-19 and progressing cancer have a higher risk of death. Data from the COVID-19 and Cancer Consortium (CCC19) registry have shown that certain subgroups of patients with cancer are at a higher risk of COVID-19–related death, including older patients, men, former smokers, those with poor performance status, and those with multiple comorbidities. In addition, their findings have also shown a higher mortality risk among patients with hematologic malignancies.
High Mortality in Subgroups
In the current study, UK researchers investigated the COVID-19 risks according to tumor subtype and patient demographics among patients with cancer in the UK.
They compared adults with cancer enrolled in the UKCCMP cohort between March 18 and May 8, 2020, with a non-COVID-19 UK cancer control population from the UK Office for National Statistics. The primary endpoint was the effect of the primary tumor subtype, age, and sex on COVID-19 prevalence and the case-fatality rate while hospitalized.
The cohort included 1044 patients from the UKCCMP and 282,878 controls. The most common solid tumor types in the COVID-19 cohort were breast (13.7%), colorectal (11.9%), prostate (10.9%), and lung (10.6%). Leukemia and lymphoma (7.6% each) were the most common hematologic malignancies, followed by myeloma (3.5%), and other types (2.8%).
A total of 319 (30.6%) patients in the UKCCMP cohort died, with 295 (92.5%) deaths related to COVID-19 infection.
Overall, patients with hematologic malignancies experienced a more severe COVID-19 trajectory compared to those with solid organ tumors (OR, 1.57; P < .0043). After correcting for age and sex, recent chemotherapy was also associated with an increased risk of death during COVID-19–associated hospital admission (OR, 2.09; P = .028).